Gain access to exclusive preclinical content.
Complete the form below. We'll assign a user name and password, then send you a link. Thanks!

Get Access Register

EXCLUSIVE PRECLINICAL CONTENT.
You must log in to access content on this page. Or click here to request access.
New MediBeacon Translational Research Presented at SPIE Photonics West

MediBeacon™ Inc. Presents Preliminary Research Findings on Novel Gastrointestinal Permeability Measurement Technique

(SAN FRANCISCO, CA, January 30, 2016) – Dr. Richard B. Dorshow, Ph.D., President, Chief Scientific Officer and co-founder of MediBeacon presented initial findings on a novel technique employing fluorescent tracer agents to measure gastrointestinal permeability. This presentation was part of the “Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications” conference within the International Biomedical Optics Symposium (BiOS 2016) on January 30, 2016 in San Francisco.

BIOS is the world's largest biomedical optics conference. It is held annually as part of SPIE Photonics West. SPIE Photonics West is the largest and most influential conference (20,000 attendees, two exhibitions, 1,300 exhibiting companies, 4,500+ papers) for biophotonics, biomedical optics, translational research, industrial lasers, optoelectronics, microfabrication, optical MEMs, and more.

The talk entitled “Application of Fluorescent Tracer Agent Technology to Point-of-Care Gastrointestinal Permeability Measurement”, was co-authored by Richard B. Dorshow, Jeng-Jong Shieh, and Thomas E. Rogers of MediBeacon Inc., and Carla Hall-Moore, Nurmohammad Shaikh, Michael Talcott, and Phillip I. Tarr of Washington University in St. Louis.

A manuscript for submission to a peer-reviewed journal is under preparation. The proceedings paper will be made available on MediBeacon’s web site.

Download as PDF

About MediBeacon Inc.
MediBeacon was formed in 2012 specifically to acquire the optical diagnostic program from Mallinckrodt, the Pharmaceuticals business of Covidien. MediBeacon’s mission is to commercialize biocompatible optical diagnostic agents for physiological monitoring, surgical guidance, and imaging of pathological disease in the human population. Several product concepts in these arenas are contained in the MediBeacon Intellectual Property estate.

Learn more about MediBeacon at www.medibeacon.com.

# # #

CONTACT:
Steve Hanley
MediBeacon Inc.
Office - 314-269-5808
Email - hanley@medibeacon.com
www.medibeacon.com

1100 Corporate Square Drive
Helix Center, Suite 175
St Louis MO 63132